Tuesday, November 2, 2021; 8:45 AM - 10:45 AM
Section outline
-
LGD: Quantifying the benefits and harms of treatments using RCTS / Alternatives to RCTs
RCT checklist; importance of baseline incidence; measures of effect size: Relative risk (RR), relative risk reduction (RRR), Odds ratio (OR), Absolute risk reduction (ARR), Number needed to treat (NNT); "Back of the Envelope Cost Effectiveness Analysis"Faculty: Thomas Newman
-
Lecture 7 Part 1, (Introduction and critical appraisal of RCTs; 37:52) 2020-1028 URL
-
Lecture 7, Part 2 (Quantifying treatment effects; 42:33) 2020-1028 URL
-
Zoom Recording of Large Group Discussion 11/2/2021 Media Resource
-
This is an expanded version of Table 8.1 created by Nicole Rodriquez.
-
LeNoury 2015 BMJ Restoring Study 329 File
-
Newman 2004 NEJM Antidepressant Perspective File
-
Stempel 2016 NEJM AUSTRI study Advair v fluticasone alone File
-
Stolker 2014 Circulation rethinking composite endpoints in clinical trials File
-
Ciani 2013 BMJ Surrogate vs patient relevant outcomes File
-
Miner 2017 Am J Gastro Pecanatide for chronic constipation File
-
This recording has some of the same examples as the lecture on Chapter 8; feel free to skip around.